Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
December 16, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 16, 2002
- Nippon Chemiphar: Uralyt Sales Strong but Less than Expected
December 9, 2002
- REGULATORY NEWS IN BRIEF
December 9, 2002
- Nikken Chemicals: Ethical Drug Sales Down 3.7% in 1st Half
December 9, 2002
- Kyowa Hakko to Collect Evidence on Coniel from Large Study
December 9, 2002
- Fukujin: Sales Up 14.2%, Profit Up 80.9%
December 9, 2002
- Matsumotokiyoshi: Sales Up 4.2%, Operating Profits Up 21%
December 9, 2002
- VITAL-NET: Sales Up, Operating Profits Jump
December 9, 2002
- Takeda to Start Joint Drug Discovery with Albany Molecular Research
December 9, 2002
- PhRMA Issues Program for 21st Century Health Reform in Japan
December 9, 2002
- Atol: Net Profits Down 16.3% Despite Higher Sales
December 9, 2002
- NanoCarrier, Kirin to Collaborate on Novel Anticancer Agents
December 9, 2002
- Bayer AG Actively Seeking Alliance: Mr Wenning
December 9, 2002
- Astis: Sales Up 0.9% to \44.7 Bil.
December 9, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 9, 2002
- Sankyo to Spin Off Agricultural Chemicals, Specialty Products
December 9, 2002
- Seiwa Sangyo: 4.5% Increase in Sales Boosts Profits
December 9, 2002
- Kobayashi Pharma: New Products, Cost-cutting Boost Sales and Profits
December 9, 2002
- BUSINESS NEWS IN BRIEF
December 9, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…